About the Company
exelixis is a biopharmaceutical company focused on developing and commercializing small molecule therapies with the potential to improve the treatment of cancer. over the past decade, we have established a broad development platform, laying the foundation for our continued efforts to bring new therapies for cancer to patients in need. our first commercial product, cometriq® (cabozantinib), received its initial regulatory approval in late 2012. we are committed to excellence in all aspects of our business and are dedicated to improving the care of, and outcomes for, patients with cancer. for more information about the company and potential job opportunities, please visit our website at www.exelixis.com.
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology
Employees
484
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $EXEL News
Exelixis (EXEL) Q4 Earnings Beat on Lower R&D Spend, Sales Miss
Exelixis, Inc. EXEL reported earnings of 33 cents per share in the fourth quarter of 2023, which beat the Zacks Consensus Estimate of 31 cents. The company posted a net loss of 3 cents per share ...
Why Is $7B Valued Cancer Focused Exelixis Trading Lower Today?
Sunday, Exelixis Inc (NASDAQ: EXEL) provided financial guidance for fiscal year 2024 and delivered an update on its business. The company announced preliminary FY23 revenue of $1.83 billion versus ...
Exelixis, Inc.: Exelixis Earnings: Cabometyx Posts Strong Sales, but Patent Expirations Present Long-Term Concerns
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic ...
Exelixis (NASDAQ: EXEL)
Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx ...
Exelixis, Inc. (EXEL) Q4 2023 Earnings Call Transcript
Good day, ladies and gentlemen, and welcome to the Exelixis Fourth Quarter and Fiscal Year 2023 Financial Results Conference Call. My name is Tawanda, and I will be your operator for today.
Exelixis: Q4 Earnings Snapshot
ALAMEDA, Calif. (AP) — ALAMEDA, Calif. (AP) — Exelixis Inc. (EXEL) on Tuesday reported fourth-quarter earnings of $85.5 million. On a per-share basis, the Alameda, California-based company ...
Exelixis, Inc. (EXEL)
Overall score is calculated based on proprietary scores based on sector averages in key company indicators: fair value, dividends, innovation, hiring, and insider sentiment. Note: if you don't see ...
Exelixis' Growth Trajectory Depends on Leading Innovations in Cancer Treatments
In recent years, the company's management has continued to delight investors with significant growth in its commercial ...
Loading the latest forecasts...